Eli Lilly stock surged about 5% in premarket trading on August 5, 2026, after the pharmaceutical giant raised its full-year revenue guidance to $85 billion to $87 billion, up from a previous range of $82 billion to $85 billion, driven by stronger-than-expected demand for its weight-loss and diabetes drugs.
The guidance increase came as Eli Lilly reported second-quarter revenue of $23.0 billion, a 48% increase from the prior-year quarter, according to the company’s earnings announcement. The surge was fueled primarily by blockbuster sales of Mounjaro, which increased 91% to $9.9 billion, and Zepbound, which rose 46% to $4.9 billion.
Eli Lilly’s second-quarter adjusted earnings per share jumped 33% to $8.38, exceeding analyst expectations. The company’s gross margin expanded to 85.8% of revenue, a 1.5 percentage point increase from the same quarter last year, driven by improved production costs and favorable product mix despite lower realized prices for its GLP-1 medications.
The GLP-1 market—drugs designed for diabetes and weight loss—has become a major growth engine for Eli Lilly. According to market research, the global GLP-1 receptor agonist market is projected to grow from $58 billion in 2026 to $132.79 billion by 2035, driven by expanding uses, rising obesity rates, and increased access and affordability. Mounjaro and Zepbound now represent the company’s fastest-growing revenue drivers, with international sales of Mounjaro surging particularly in China after the drug was added to the country’s National Reimbursement Drug List in early 2026.
Beyond the weight-loss drug momentum, Eli Lilly’s pipeline is expanding through both internal development and acquisitions. The company announced regulatory approvals for its atopic dermatitis treatment Ebglyss and reported positive Phase 3 trial data for retatrutide, a next-generation triple agonist for obesity, with plans to submit a biologics license application to the FDA in the first quarter of 2027. In the second quarter alone, Lilly completed acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics to strengthen its pipeline across infectious disease, sleep-wake disorders, and other therapeutic areas.
The revenue guidance raise reflects broader momentum in the pharmaceutical sector when companies exceed earnings expectations and raise outlooks. In July 2026, Abbott Laboratories surged its highest level in 24 years after raising 2026 profit guidance following a stronger-than-expected second quarter. The pattern shows that guidance raises tied to blockbuster drug sales tend to drive significant investor confidence and stock appreciation in the near term.
Eli Lilly also committed an additional $4.5 billion to expand its Indiana manufacturing sites, signaling confidence in sustained demand for its GLP-1 products and positioning the company to meet anticipated global appetite for weight-loss and diabetes treatments through the remainder of 2026 and beyond.
Sources
- PR Newswire — Eli Lilly’s official Q2 2026 earnings announcement, including revenue guidance raise to $85–$87 billion, Mounjaro and Zepbound sales figures, and pipeline updates
- MedWatch — Confirmation of 5.6% premarket stock surge and adjusted EPS increase of 33% to $8.38
- Reuters — Eli Lilly’s updated 2026 revenue forecast and analysis of GLP-1 drug demand
- Toward Healthcare — GLP-1 market size projections from $58.05 billion in 2026 to $132.79 billion by 2035
- Bloomberg Law — Abbott Laboratories precedent: 24-year stock surge on 2026 guidance raise following Q2 earnings beat
